Author: Jessica.F

On June 25, 2015, Stockwell, Brent R.; Welsch, Matthew; Yang, Wan Seok published a patent.Application In Synthesis of 5-Bromo-2-isopropoxyaniline The title of the patent was Quinazolinone-based oncogenic-ras-selective lethal compounds and their use. And the patent contained the following:

The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided. The experimental process involved the reaction of 5-Bromo-2-isopropoxyaniline(cas: 1019442-22-8).Application In Synthesis of 5-Bromo-2-isopropoxyaniline

The Article related to antitumor quinazolinone preparation oncogenic ras mutation cancer therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 5-Bromo-2-isopropoxyaniline

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On July 17, 2014, Boruah, Anima; Hosahalli, Subramanya; Panigrahi, Sunil Kumar published a patent.Related Products of 1261475-16-4 The title of the patent was Substituted 2-pyrazinone derivatives as kinase inhibitors. And the patent contained the following:

The present invention provides novel substituted 2-pyrazinone derivatives (I) as protein kinase inhibitors that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The experimental process involved the reaction of 1-Bromo-3-isocyanato-2-methyl-benzene(cas: 1261475-16-4).Related Products of 1261475-16-4

The Article related to btk kinase inhibitor pyrazinone derivative preparation cancer autoimmune inflammation, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Related Products of 1261475-16-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 28, 2020, Kim, Jong Seung; Sunwoo, Gyeong; Verwilst, Peter; Won, Mi Ae published a patent.COA of Formula: C24H27Br2P The title of the patent was Modified antibiotics for non-nuclear genotoxic chemotherapy and pharmaceutical composition for anti-cancer containing the same. And the patent contained the following:

The present invention relates to a modified antibiotic compound for the treatment of cancer with minimal nuclear gene damage and an anticancer pharmaceutical composition comprising same. Since the repurposed antibiotic compound has a therapeutic effect in a manner that targets only the mitochondria of cancer cells, the modified antibiotic compound does not cause gene degeneration unlike conventional chemotherapy which damages nuclear DNAs to kill cancer cells, , thereby preventing the recurrence of cancer. In addition, a mitochondria targeted therapy using the compound according to the present invention can effectively treat malignant tumors that are difficult to treat due to acquiring drug resistance by general anticancer treatment. The experimental process involved the reaction of (6-Bromohexyl)triphenylphosphonium bromide(cas: 83152-22-1).COA of Formula: C24H27Br2P

The Article related to nonnuclear genotoxic chemotherapy mitochondria targeting antimetastatic repurposed antibiotic, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.COA of Formula: C24H27Br2P

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 24, 2020, Kim, Jong Seung; Sunwoo, Kyoung; Verwilst, Peter; Won, Miae published a patent.Formula: C24H27Br2P The title of the patent was Repurposed antibiotics for non-nuclear genotoxic chemotherapy and pharmaceutical composition for anti-cancer containing the same. And the patent contained the following:

The present invention relates to a repurposed antibiotic compound for the treatment of cancer with minimal nuclear gene damage and an anticancer pharmaceutical composition comprising same. Since the repurposed antibiotic compound has a therapeutic effect in a manner that targets only the mitochondria of cancer cells, the modified antibiotic compound does not cause gene degeneration unlike conventional chemotherapy which damages nuclear DNAs to kill cancer cells, , thereby preventing the recurrence of cancer. In addition, a mitochondria targeted therapy using the compound according to the present invention can effectively treat malignant tumors that are difficult to treat due to acquiring drug resistance by general anticancer treatment. The experimental process involved the reaction of (6-Bromohexyl)triphenylphosphonium bromide(cas: 83152-22-1).Formula: C24H27Br2P

The Article related to nonnuclear genotoxic chemotherapy mitochondria targeting antimetastatic repurposed antibiotic, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Formula: C24H27Br2P

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Min, Rui; Wu, Weibin; Wang, Mingzhong; Tang, Lin; Chen, Dawei; Zhao, Huan; Zhang, Cunlong; Jiang, Yuyang published an article in 2019, the title of the article was Discovery of 2-(1-(3-(4-chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: a potent poly(ADP-ribose) polymerase (PARP) inhibitor for treatment of cancer.SDS of cas: 574-98-1 And the article contains the following content:

A series of benzimidazole carboxamide derivatives have been synthesized and characterized by 1H-NMR, 13C-NMR and HRMS. PARP inhibition assays and cellular proliferation assays have also been carried out. Compounds 5cj and 5cp exhibited potential anticancer activities with IC50 values of about 4 nM against both PARP-1 and PARP-2, similar to the reference drug veliparib. The two compounds also displayed slightly better in vitro cytotoxicities against MDA-MB-436 and CAPAN-1 cell lines than veliparib and olaparib, with values of 17.4 microM and 11.4 microM, 19.8 microM and 15.5 microM, resp. The structure-activity relationship based on mol. docking was discussed as well. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).SDS of cas: 574-98-1

The Article related to breast cancer parp inhibitor, parp enzyme inhibition, benzimidazole carboxamide, poly(adp-ribose) polymerase, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.SDS of cas: 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On March 15, 2019, Miyake, Yuka; Itoh, Yukihiro; Hatanaka, Atsushi; Suzuma, Yoshinori; Suzuki, Miki; Kodama, Hidehiko; Arai, Yoshinobu; Suzuki, Takayoshi published an article.Formula: C10H8BrNO2 The title of the article was Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy. And the article contained the following:

Histone lysine demethylases (KDMs) have drawn much attention as targets of therapeutic agents. KDM5 proteins, which are Fe(II)/α-ketoglutarate-dependent demethylases, are associated with oncogenesis and drug resistance in cancer cells, and KDM5-selective inhibitors are expected to be anticancer drugs. However, few cell-active KDM5 inhibitors have been reported and there is an obvious need to discover more. In this study, we pursued the identification of highly potent and cell-active KDM5-selective inhibitors. Based on the reported KDM5 inhibitors, we designed several compounds by strategically merging two fragments for competitive inhibition with α-ketoglutarate and for KDM5-selective inhibition. Among them, compounds 10 and 13, which have a 3-cyano pyrazolo[1,5-a]pyrimidin-7-one scaffold, exhibited strong KDM5-inhibitory activity and significant KDM5 selectivity. In cellular assays using human lung cancer cell line A549, 10 and 13 increased the levels of trimethylated lysine 4 on histone H3, which is a specific substrate of KDM5s, and induced growth inhibition of A549 cells. These results should provide a basis for the development of cell-active KDM5 inhibitors to highlight the validity of our inhibitor-based fragment merging strategy. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Formula: C10H8BrNO2

The Article related to lysine demethylase kdm5 inhibitor drug design histone methylation epigenetics, epigenetics, histone methylation, inhibitor design, jhdm, kdm, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Formula: C10H8BrNO2

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On June 7, 2021, You, Lijun; Yuan, Wei; He, Chuan published an article.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl The title of the article was Intermolecular Dehydrogenative C-H/Si-H Cross-Coupling for the Synthesis of Arylbenzyl Bis(silanes). And the article contained the following:

An Ir-catalyzed intermol. dehydrogenative C-H/Si-H cross-coupling reaction for the synthesis of arylbenzyl bis(silanes) is developed. This hydrosilyl group steered intermol. C-H silylation process features high chemo- and regioselectivity, giving access to a wide range of multi-functionalized organosilanes in good yields from readily available starting materials with atom economy, efficiency, and environmental benignity. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Quality Control of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to benzhydryldimethylsilane iridium catalyzed intermol dehydrogenative cross coupling phenyldimethylsilane, crystal structure arylbenzyl bissilane, mol structure, Organometallic and Organometalloidal Compounds: Silicon Compounds and other aspects.Quality Control of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Yu, Xi-Hui; Cai, Xiong-Jie; Hong, Xiao-Qiao; Tam, Kin Yip; Zhang, Kun; Chen, Wen-Hua published an article in 2019, the title of the article was Synthesis and biological evaluation of aza-crown ether-squaramide conjugates as anion/cation symporters.Electric Literature of 574-98-1 And the article contains the following content:

Anion/cation symport across cellular membranes may lead to cell apoptosis and be developed as a strategy for new anticancer drug discovery. Four aza-crown ether-squaramide conjugates were synthesized and characterized. Their anion recognition, anion/cation symport, cytotoxicity and probable mechanism of action were investigated in details. These conjugates are able to form ion-pairing complexes with chloride anions and facilitate the transmembrane transport of anions via an anion/cation symport process. They can disrupt the cellular homeostasis of chloride anions and sodium cations and induce the basification of acidic organelles in live cells. These conjugates exhibit moderate cytotoxicity toward the tested cancer cells and trigger cell apoptosis by mediating the influx of chloride anions and sodium cations into live cells. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Electric Literature of 574-98-1

The Article related to aza ether squaramide anion cation cervical cancer antitumor agent, anion/cation symporter, anionophoric activity, antiproliferative activity, aza-crown ether, squaramide, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Electric Literature of 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On September 15, 2011, Yeung, Kap-Sun; Parcella, Kyle E.; Bender, John A.; Beno, Brett R.; Grant-Young, Katharine A.; Han, Ying; Hewawasam, Piyasena; Kadow, John F.; Nickel, Andrew published a patent.Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid The title of the patent was Preparation of benzofurancarboxamide derivatives and their preparation and use for the treatment of hepatitis C. And the patent contained the following:

The invention relates to benzofurancarboxamide derivatives of formula I, which are useful for treatment of hepatitis C. Compounds of formula I wherein R1 is NR5R6, alkoxy, Ph, etc.; R2 is H, halo, NO2, NH2, Ph and NR5R6; R3 is CN, alkoxycarbonyl, (cycloalkyl)oxycarbonyl, etc.; R4 is substituted Ph; R5 is H, alkyl and alkylsulfonyl; R6 is H, alkyl, hydroxyalkyl, alkoxyalkyl and alkylsulfonyl; R20 and R21 are independently H, halo, alkyl and alkoxy; and pharmaceutically acceptable salts thereof, are disclosed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their activity against HCV. From the assay, it was determined that compound II exhibited IC50 and EC50 values in the range 0.002 – 0.25 μM, resp. The experimental process involved the reaction of 5-Bromo-2-methoxy-4-methylbenzoic acid(cas: 90326-61-7).Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid

The Article related to benzofurancarboxamide preparation treatment hepatitis c, Heterocyclic Compounds (One Hetero Atom): Areno- and Diarenofurans and other aspects.Quality Control of 5-Bromo-2-methoxy-4-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Asadi, Mehdi; Ebrahimi, Mostafa; Mohammadi-Khanaposhtani, Maryam; Azizian, Homa; Sepehri, Saghi; Nadri, Hamid; Biglar, Mahmood; Amanlou, Massoud; Larijani, Bagher; Mirzazadeh, Roghieh; Edraki, Najmeh; Mahdavi, Mohammad published an article in 2019, the title of the article was Design, synthesis, molecular docking, and cholinesterase inhibitory potential of phthalimide-dithiocarbamate hybrids as new agents for treatment of Alzheimer’s disease.Product Details of 574-98-1 And the article contains the following content:

A novel series of phthalimide-dithiocarbamate hybrids was synthesized and evaluated for in vitro inhibitory potentials against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The anti-cholinesterase results indicated that among the synthesized compounds, the compounds 7g and 7h showed the most potent anti-AChE and anti-BuChE activities, resp. Mol. docking and dynamic studies of the compounds 7g and 7h, resp., in the active site of AChE and BuChE revealed that these compounds as well interacted with studied cholinesterases. These compounds also possessed drug-like properties and were able to cross the BBB. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Product Details of 574-98-1

The Article related to synthesis docking cholinesterase inhibitor phthalimide dithiocarbamate hybrid antialzheimer, alzheimer’s disease, acetylcholinesterase, butyrylcholinesterase, dithiocarbamate, inhibitory activity, phthalimide and other aspects.Product Details of 574-98-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary